Production of virus-like particles for vaccines.
Saved in:
| Title: | Production of virus-like particles for vaccines. |
|---|---|
| Authors: | Fuenmayor, J.1 javier.fuenmayor@uab.cat, Gòdia, F.1, Cervera, L.2 |
| Source: | New Biotechnology. Oct2017 Part B, Vol. 39, p174-180. 7p. |
| Subjects: | Virus-like particles, Vaccines, Immune response, Post-translational modification, Lipids |
| Abstract: | Virus-like particles (VLPs) are nanostructures that resemble the structures of viruses. They are composed of one or more structural proteins that can be arranged in several layers and can also contain a lipid outer envelope. VLPs trigger a high humoral and cellular immune response due to their repetitive structures. A key factor regarding VLP safety is the lack of viral genomic material, which enhances safety during both manufacture and administration. Contemporary VLP production may take advantage of several systems, including bacterial, yeast, insect and mammalian cells. The choice of production platform depends on several factors, including cost and the need for post-translational modifications (PTMs), which can be essential in generating an optimal immune response. Some VLP-based vaccines designed to prevent several infectious diseases are already approved and on the market, with many others at the clinical trial or research stage. Interest in this technology has recently increased due to its advantages over classical vaccines. This paper reviews the state-of-the-art of VLP production systems and the newest generation of VLP-based vaccines now available. [ABSTRACT FROM AUTHOR] |
| Copyright of New Biotechnology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: egs DbLabel: Engineering Source An: 125704603 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Production of virus-like particles for vaccines. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Fuenmayor%2C+J%2E%22">Fuenmayor, J.</searchLink><relatesTo>1</relatesTo><i> javier.fuenmayor@uab.cat</i><br /><searchLink fieldCode="AR" term="%22Gòdia%2C+F%2E%22">Gòdia, F.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Cervera%2C+L%2E%22">Cervera, L.</searchLink><relatesTo>2</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22New+Biotechnology%22">New Biotechnology</searchLink>. Oct2017 Part B, Vol. 39, p174-180. 7p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Virus-like+particles%22">Virus-like particles</searchLink><br /><searchLink fieldCode="DE" term="%22Vaccines%22">Vaccines</searchLink><br /><searchLink fieldCode="DE" term="%22Immune+response%22">Immune response</searchLink><br /><searchLink fieldCode="DE" term="%22Post-translational+modification%22">Post-translational modification</searchLink><br /><searchLink fieldCode="DE" term="%22Lipids%22">Lipids</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Virus-like particles (VLPs) are nanostructures that resemble the structures of viruses. They are composed of one or more structural proteins that can be arranged in several layers and can also contain a lipid outer envelope. VLPs trigger a high humoral and cellular immune response due to their repetitive structures. A key factor regarding VLP safety is the lack of viral genomic material, which enhances safety during both manufacture and administration. Contemporary VLP production may take advantage of several systems, including bacterial, yeast, insect and mammalian cells. The choice of production platform depends on several factors, including cost and the need for post-translational modifications (PTMs), which can be essential in generating an optimal immune response. Some VLP-based vaccines designed to prevent several infectious diseases are already approved and on the market, with many others at the clinical trial or research stage. Interest in this technology has recently increased due to its advantages over classical vaccines. This paper reviews the state-of-the-art of VLP production systems and the newest generation of VLP-based vaccines now available. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of New Biotechnology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=125704603 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.nbt.2017.07.010 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 7 StartPage: 174 Subjects: – SubjectFull: Virus-like particles Type: general – SubjectFull: Vaccines Type: general – SubjectFull: Immune response Type: general – SubjectFull: Post-translational modification Type: general – SubjectFull: Lipids Type: general Titles: – TitleFull: Production of virus-like particles for vaccines. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Fuenmayor, J. – PersonEntity: Name: NameFull: Gòdia, F. – PersonEntity: Name: NameFull: Cervera, L. IsPartOfRelationships: – BibEntity: Dates: – D: 26 M: 10 Text: Oct2017 Part B Type: published Y: 2017 Identifiers: – Type: issn-print Value: 18716784 Numbering: – Type: volume Value: 39 Titles: – TitleFull: New Biotechnology Type: main |
| ResultId | 1 |
